The steep incline of insulin prices will soon come to a halt with Senate Bill 90, newly introduced by California state Senator Scott Weiner (D-San Francisco). This bill aims to amend healthcare coverage for diabetics and introduces a cap on insulin prices at $35 for a 30-day supply.

If passed, this bill will prevent healthcare insurance plan contracts or disability insurance policies, begun or renewed by January 1, 2024, from enforcing a deductible on insulin prescriptions. The creation of a state-mandated local program within SB 90 will protect patients’ financial wellbeing by preventing Pharmacy Benefit Managers (PBMs) and insurers from abusing loopholes.

A similar policy was enacted by insulin manufacturer Eli Lilly and Company during the peak of the COVID-19 crisis. The company created a value program to provide aid during mass layoffs and economic turmoil, with advocates stating: “It’s critical that people with diabetes can reliably access insulin at a low, consistent out-of-pocket cost. Enabling a $35 per month insulin copay, regardless of employment status, will help many Americans in this difficult time.”.

Price protection for insulin has been long overdue, with diabetics often overpaying for their lifesaving medications. SB 90 will create tremendous waves within the market by requiring the insurance industry to cover the cost of treatment. Insurance accountability is essential to maintain healthcare transparency; the misuse of this system has resulted in diabetic patients being forced to ration their insulin supply due to rising costs that have tripled over time. Approximately 4,037,000 Californians currently live with diabetes and rely on insulin each day to survive.